The single biggest practical difference is how you take them: Foundayo can be taken at any time of day, with or without food or water, while the Wegovy pill must be taken on an empty stomach with a small sip of water, followed by a strict 30-minute wait before eating, drinking, or taking other oral medicines. In clinical trials, Wegovy's pill produced greater average weight loss (16.6% at 64 weeks, assuming full treatment adherence) than Foundayo has shown at its approved maximum dose (11.1% at 72 weeks) — though the two haven't been tested head-to-head, so this isn't a direct comparison. Right now, the most important practical difference is availability: the Wegovy pill is already available to order through Happy Pharmacy, while Foundayo is still awaiting UK launch following its MHRA authorisation.
This is where the two medicines genuinely diverge, and it comes down to their underlying chemistry. Foundayo is a small, non-peptide molecule, while the Wegovy pill delivers a peptide (semaglutide, the same active ingredient as the Wegovy injection) using an absorption-enhancing ingredient called SNAC to survive digestion. That difference in formulation is exactly why their administration requirements are so different.
| Foundayo | Wegovy Pill | |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| Active ingredient | Orforglipron (small molecule) | Semaglutide (peptide) |
| Food/water restriction | None — any time of day | Empty stomach, sip of water only, then 30-minute wait |
| Absorption enhancer needed | No | Yes (SNAC) |
Why this matters day to day
For many people, the Wegovy pill's fasting requirement is manageable with a consistent morning routine — take it, wait, then have breakfast. But for anyone with an irregular schedule, shift work, or who simply doesn't want to plan their morning around a tablet, Foundayo's complete lack of food or water restriction is a genuine, practical advantage.
It's important to be upfront here: Foundayo and the Wegovy pill haven't been tested against each other in a head-to-head trial, so any comparison is between two separate trials with different designs, populations and timeframes — not a controlled, direct comparison.
| Foundayo (ATTAIN-1) | Wegovy Pill (OASIS 4) | |
|---|---|---|
| Trial duration | 72 weeks | 64 weeks |
| Average weight loss (highest dose) | 11.1% | 16.6% (assuming full treatment adherence) |
| Placebo group | 2.1% | 2.7% |
| Participants achieving ≥20% weight loss | 18.4% (17.2mg dose) | 30% |
On these figures, the Wegovy pill's trial showed a larger average effect — but trial populations, adherence assumptions, and study design all differ enough that this shouldn't be read as "the Wegovy pill definitely works better for you." Individual response to any GLP-1 medicine varies considerably, and your own results depend on your dose, your adherence, and your individual biology, not just the trial average.
| Foundayo | Wegovy Pill | |
|---|---|---|
| Starting dose | 0.8mg | 1.5mg |
| Number of steps | 6 | 4 |
| Minimum time per step | 30 days | 28 days (1 month) |
| Maximum dose | 17.2mg | 25mg |
Foundayo's extra titration steps reflect a more gradual early dose increase, though both medicines take roughly four to five months to reach their respective maximum doses if following every step without pausing. For the complete Foundayo schedule, see our dedicated dosage and titration guide.
Side Effects ComparedBoth medicines share a broadly similar side-effect profile, dominated by gastrointestinal symptoms — nausea, diarrhoea, vomiting, constipation and indigestion are the most commonly reported for both, particularly during dose escalation. Foundayo's lack of a SNAC absorption enhancer may make it more comfortable for some people, since SNAC is itself a recognised cause of stomach irritation — though current evidence doesn't clearly establish one medicine as better tolerated overall than the other.
One side-effect-adjacent consideration both medicines share: because both slow gastric emptying, both can reduce the absorption of other oral medicines taken around the same time, including hormonal contraceptives. This isn't unique to either drug — it's a feature of the GLP-1 class — but it's worth discussing with your prescriber whichever tablet you choose. For more detail, see our Foundayo side effects guide.
Important
Neither medicine should be combined with another GLP-1 receptor agonist medicine, including each other, Mounjaro, or the Wegovy injection. If you're considering switching between any of these treatments, this should always be planned with your prescriber, typically with a short washout period.
The Wegovy injection holds a specific UK licence for reducing cardiovascular risk in people with established cardiovascular disease, based on the SELECT trial. In the US, Novo Nordisk's Wegovy tablet has also gained this same cardiovascular indication — but as of now, this hasn't been confirmed as part of the UK-licensed indication for the tablet specifically, so this shouldn't be assumed without checking the current UK SmPC. Foundayo doesn't currently carry a cardiovascular indication in any market, though a dedicated cardiovascular outcomes trial (ATTAIN-Outcomes) is underway, including UK trial sites.
If You're Already on Another GLP-1 MedicineBoth Foundayo and the Wegovy pill are genuinely new treatment options for people who are either starting GLP-1 treatment for the first time, or considering a change from an existing injectable medicine. If you're currently on Mounjaro or the Wegovy injection and considering either oral option, it's worth knowing that switching isn't a like-for-like dose swap — both Foundayo and the Wegovy pill are started at their own low initial dose and titrated up from there, regardless of what dose you were taking on your previous treatment. Lilly's own clinical trial programme (ATTAIN-MAINTAIN) has specifically studied switching from injectable tirzepatide or semaglutide to Foundayo, and found that people generally maintained their previous weight loss after switching — useful context if you're considering moving from an injection to a tablet rather than starting from scratch.
A Genuinely New Kind of ChoiceUntil relatively recently, anyone wanting a GLP-1 medicine in the UK had one real choice to make: which injection. The arrival of two chemically different oral options — not just two brands of the same molecule — is a genuinely new situation for UK patients. Foundayo and the Wegovy pill aren't simply competing versions of the same tablet; they represent two different scientific approaches (small-molecule vs peptide) to the same underlying goal, each with its own trade-offs in convenience, trial results, and manufacturer backing. Neither is a straightforwardly "better" choice in the abstract — the right one depends on what matters most to you, and that's exactly the kind of decision a proper consultation is designed to help with, rather than a trial statistic on its own.
Which Might Suit You BetterFoundayo may suit you if…
- You have an unpredictable schedule and don't want to plan your morning around a fasting window
- You'd rather take a small-molecule drug than a peptide — orforglipron is a non-peptide GLP-1 receptor agonist, so it doesn't need an absorption enhancer to survive the stomach at all
- You're comfortable waiting for UK launch, or want to register interest now to be first in line
The Wegovy Pill may suit you if…
- You want to start an oral GLP-1 treatment today rather than waiting
- You already have a consistent morning routine and don't mind the empty-stomach requirement
- Maximum average weight loss, based on trial data, is your priority
Start Today, or Wait for Foundayo® — Either Way, We're Here
The Wegovy pill is available to order now through Happy Pharmacy following a free online consultation. If you'd rather wait for Foundayo®, register your interest and we'll let you know the moment it's available.
Start Your Free Online Consultation → Use code SWITCH10 if you're switching from another providerHappy Pharmacy is a GPhC-registered pharmacy (No. 9012585) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot
- Foundayo® (orforglipron) Summary of Product Characteristics, MHRA Products website.
- Wharton S, et al. ATTAIN-1. N Engl J Med, September 2025.
- Eli Lilly and Company. Foundayo™ (orforglipron) Medication Guide and full Prescribing Information, lilly.com.
- Wegovy® 25mg tablets, UK Summary of Product Characteristics, medicines.org.uk (emc).
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087.
- Novo Nordisk. Wegovy® Pill Guide and Dosing Information, novomedlink.com / wegovy.com.
- MHRA. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes, 10 August 2026.
- MHRA. Approval of oral semaglutide (Wegovy pill), 11 June 2026.